Company Overview - Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs) [4] - The company leverages its proprietary technology platform called GEODe™ (GPCRs Engineered for Optimal Discovery) to develop biologic medicines aimed at overcoming challenges in GPCR-targeted drug discovery [4] - Tectonic targets areas of significant unmet medical need, where therapeutic options are limited or nonexistent, to improve patient quality of life [4] Recent Developments - Tectonic has been added to the Russell 3000 Index following the conclusion of the 2025 Russell US Indexes annual reconstitution, effective after the open of US equity markets on June 30, 2025 [1] - Membership in the Russell 3000 Index results in automatic inclusion in either the large-cap Russell 1000® Index or small-cap Russell 2000® Index, along with the appropriate growth and value style indexes [2]
Tectonic Therapeutic Joins Russell 3000® Index